Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Chlorpromazine hydrochloride
Drug ID BADD_D00446
Description The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.
Indications and Usage For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.
Marketing Status Discontinued; Prescription
ATC Code N05AA01
DrugBank ID DB00477
KEGG ID D00789
MeSH ID D002746
PubChem ID 6240
TTD Drug ID D01ZII
NDC Product Code 60687-441; 69238-1054; 0832-6021; 70710-1129; 60687-430; 0527-2961; 69238-1056; 70518-3321; 70771-1506; 0832-0302; 0832-0301; 0904-7129; 0904-6894; 70518-1608; 70771-1507; 60687-452; 42413-0137; 68462-863; 0641-1397; 0527-2965; 70771-1510; 69238-1058; 70771-1509; 60687-419; 70710-1131; 0832-6020; 0832-0304; 55150-318; 90096-135; 0404-9836; 0904-6896; 52584-397; 72205-106; 90096-134; 68462-864; 72205-105; 51407-437; 24338-410; 70518-3348; 58793-013; 70518-0016; 82298-901; 50396-7515; 67763-115; 69238-1060; 73435-001; 50268-163; 0641-1398; 68462-865; 90096-131; 0904-6892; 0527-2964; 64950-241; 0904-7132; 0832-0303; 70771-1508; 90096-132; 90096-133; 69238-1062; 55150-319; 16714-047; 0781-5917; 70966-0017; 50090-2791; 68462-862; 70518-3034; 70710-1133; 24338-403; 70710-1132; 50090-2865; 16714-049; 0527-2962; 0781-5914; 71554-002; 51407-436; 50268-166; 70710-1130; 68462-861; 0904-7131; 70518-3086; 16714-050; 53808-1104; 72166-004; 70518-3280; 0781-5913; 60687-463; 50268-162; 72205-107; 0832-6019; 50268-164; 62991-1425; 0904-7133; 16714-048; 50268-165; 0832-6017; 51407-438; 38779-0423; 72205-104; 64950-240; 71666-006; 0904-6895; 0832-6018; 51552-0139; 51407-435; 51407-434; 16714-051; 0832-0300; 0527-2963; 0904-7130
Synonyms Chlorpromazine | Thorazine | Aminazine | Largactil | Chlordelazine | Chlorpromazine Hydrochloride | Hydrochloride, Chlorpromazine | Contomin | Fenactil | Propaphenin | Chlorazine
Chemical Information
Molecular Formula C17H19ClN2S.ClH
CAS Registry Number 69-09-0
SMILES CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl.Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Adverse drug reactionMuscarinic acetylcholine receptorQ53XZ3Not AvailableNot Available
HepatotoxicityAlanine aminotransferase 1Q8QZR5Not AvailableNot Available
HepatotoxicityL-lactate dehydrogenase A chainP00338T15053Not Available
Metabolic disorderOrnithine decarboxylaseP11926T60366Not Available
Metabolic disorderS-adenosylmethionine decarboxylase proenzymeP17707T55922Not Available
NystagmusNuclear receptor subfamily 4 group A member 3P51179Not AvailableNot Available
ParkinsonismNADH-ubiquinone oxidoreductase chain 1P03886Not AvailableNot Available
Tardive dyskinesiaD(2) dopamine receptorP14416T67162Not Available
Tardive dyskinesiaD(3) dopamine receptorP35462T02551Not Available
Tardive dyskinesiaD(4) dopamine receptorP21917T24983Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Agranulocytosis01.02.03.001--Not Available
Akathisia19.06.02.006; 17.01.02.002--
Amenorrhoea21.01.02.001; 05.05.01.002--
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Angioedema23.04.01.001; 10.01.05.009--Not Available
Aplastic anaemia01.03.03.002--Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Breast engorgement21.05.05.002; 18.08.02.001--Not Available
Constipation07.02.02.001--
CSF protein abnormal13.07.02.004--Not Available
Dermatitis contact23.03.04.004; 12.03.01.040; 10.01.01.003--Not Available
Dermatitis exfoliative23.03.07.001; 10.01.01.004--
Dry mouth07.06.01.002--
Dystonia17.01.03.001--Not Available
Ejaculation disorder21.03.01.002--
Eosinophilia01.02.04.001--
Extrapyramidal disorder17.01.02.007--
Eye disorder06.08.03.001--Not Available
Glycosuria20.02.01.005--
Gynaecomastia21.05.04.003; 05.05.02.003--
Haemolytic anaemia01.06.03.002--Not Available
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hyperpyrexia08.05.02.002--Not Available
Hypersensitivity10.01.03.003--
Hypoglycaemia14.06.03.001; 05.06.03.001--
Hypotension24.06.03.002--
Ileus paralytic07.02.05.001--Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Laryngeal oedema23.04.01.005; 22.04.02.001; 10.01.05.003--
The 1th Page    1 2    Next   Last    Total 2 Pages